Table 3. Cox regression model and multivariate analysis results.
| Parameters | PFS | OS | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | ||
| Treatment time | 0.033 | 0.057 | |||||
| First-line | 1 | 1 | |||||
| Second-line | 1.80 | 0.65–5.00 | 0.89 | 0.27–2.90 | |||
| Third or more | 3.94 | 1.36–11.51 | 2.75 | 0.88–8.59 | |||
| LDH | 0.071 | 0.434 | |||||
| Normal | 1 | 1 | |||||
| High | 2.16 | 0.94–4.97 | 1.44 | 0.58–3.57 | |||
| ECOG performance status score | |||||||
| 0 | 1 | 0.028 | |||||
| 1 | 4.24 | 0.54–33.3 | |||||
| 2 | 10.62 | 1.28–87.72 | |||||
| Therapeutic methods | 0.407 | ||||||
| Pembrolizumab | 1 | ||||||
| Pembro + chemo | 0.77 | 0.27–2.20 | |||||
| Pembro + target | 1.27 | 0.46–3.53 | |||||
ECOG, Eastern Cooperative Oncology Group; PFS, progression-free survival; OS, overall survival; CI, confidence interval; HR, hazard ratio; LDH, lactate dehydrogenase.